Sector Update: Health Care Stocks Extending Friday Recovery
4:06PM ET 8/12/2022 MT NewswiresHealth care stocks were mostly higher this afternoon, with the NYSE Health Care Index, the SPDR Health Care Select Sector ETF (XLV) and the Nasdaq...
Quotes Snapshot > UBX
UNITY Biotechnology Inc UBX:NASDAQ
Next Earnings date is expected on
08/16/2022
Last Price$1.31NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22
Today's Change0(0.00%)
Bid (Size)$1.35 (154)
Ask (Size)$1.36 (34)
Day Low / HighN/A - N/A
Volume94.5 M
Read more news Recent News
Sector Update: Health Care Stocks Adding to Morning Advance
1:50PM ET 8/12/2022 MT NewswiresHealth care stocks were mostly higher this afternoon, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) both gaining 1.0%. ...
Sector Update: Health Care
1:32PM ET 8/12/2022 MT NewswiresHealth care stocks were mostly higher this afternoon, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) each gaining 1.0%....
Wall Street Set for Gains Ahead of Consumer Sentiment Index
9:16AM ET 8/12/2022 MT NewswiresUS stocks were set for a higher open Friday as traders looked ahead to a reading on consumer sentiment. Dow Jones Industrial Average futures gained 0.4%,...
View all Commentary and Analysis
Unity Biotechnology (UBX) Investor Presentation - Slideshow
4:59PM ET 3/04/2022 Seeking AlphaCompany Profile
Business DescriptionUnity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA. View company web site for more details
| Address | 285 East Grand Avenue South San Francisco, California 94080 |
| Phone | +1.650.416.1192 |
| Number of Employees | 106 |
| Recent SEC Filing | 08/12/2022 10-Q |
| Chief Executive Officer & Director | Anirvan Ghosh |
| Vice President-Operations | Nathan Guz |
| Chief Financial Officer | Lynne Sullivan |
| Chief Medical Officer | Jamie Dananberg |
Company Highlights
| Price Open | $1.83 |
| Previous Close | $0.85 |
| 52 Week Range | $0.55 - 3.68 |
| Market Capitalization | $90.6 M |
| Shares Outstanding | 69.2 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/16/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.08 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -1,335.37% |
| Return on Equity | -109.24% |
Analyst Ratings as of 05/12/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |